United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024. In the quarter to June 2026, revenue fell 1.92%, EPS grew 14.0% and free cash flow grew 58.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

533.12 8.39 −1.55%
Market cap
$23.2B
P/E
17.6×
Fwd P/E
20.1×
Dividend yield
—
F-score
8/9
Altman Z
19.55
Beneish M
−2.26
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
19.32% 20.26% 19.71% 20.04%

+8 more TTM periods

Piotroski F-Score
6 7 8 8
ROA
17.33% 17.81% 17.51% 17.57%
ROIC
23.44% 23.94% 22.34% 24.42%
Return on Tangible Assets
27.28% 31.30% 27.40% 28.24%
Average Days of Receivables
35.90 35.93 40.16 34.73
Free Cash Flow per Share
25.66 23.38 23.37 25.37
Free Cash Flow
1,093.00 1,016.90 1,035.20 1,111.20
Other line items

Show all line items

Columns are period end dates